UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 386

Sortiert nach

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Blood, 2018-06, Vol.131 (25), p.2745-2760

2018

Volltextzugriff (PDF)

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Blood, 2008-06, Vol.111 (12), p.5446-5456

2008

Volltextzugriff (PDF)

Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options

Cancer, 2019-05, Vol.125 (9), p.1432-1440

2019

Volltextzugriff (PDF)

B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia

The Journal of clinical investigation, 2022-01, Vol.132 (2), p.0_1-14

2022

Volltextzugriff (PDF)

Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1349-1355

2011

Volltextzugriff (PDF)

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

The Journal of clinical investigation, 2005-03, Vol.115 (3), p.755-764

2005

Volltextzugriff (PDF)

Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2007-03, Vol.25 (9), p.1114-1120

2007

Volltextzugriff (PDF)

Chronic lymphocytic leukemia (CLL)—Then and now

American journal of hematology, 2016-03, Vol.91 (3), p.330-340

2016

Volltextzugriff (PDF)

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5208-5212

2009

Volltextzugriff (PDF)

A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice

Frontiers in immunology, 2021-03, Vol.12, p.627020-627020

2021

Volltextzugriff (PDF)

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Blood, 2002-05, Vol.99 (10), p.3554-3561

2002

Volltextzugriff (PDF)

Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia

The Journal of experimental medicine, 2004-08, Vol.200 (4), p.519-525

2004

Volltextzugriff (PDF)

CLL stereotyped B-cell receptor immunoglobulin sequences are recurrent in the B-cell repertoire of healthy individuals: Apparent lack of central and early peripheral tolerance censoring

Frontiers in oncology, 2023-03, Vol.13, p.1112879-1112879

2023

Volltextzugriff (PDF)

Correction to: Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells

Molecular medicine (Cambridge, Mass.), 2022-03, Vol.28 (1), p.35-35, Article 35

2022

Volltextzugriff (PDF)

Characterization of the Intraclonal Complexity of Chronic Lymphocytic Leukemia B Cells: Potential Influences of B-Cell Receptor Crosstalk with Other Stimuli

Cancers, 2023-09, Vol.15 (19), p.4706

2023

Volltextzugriff (PDF)

Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7697-7702

2005

Volltextzugriff (PDF)

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

Journal of clinical oncology, 2010-10, Vol.28 (29), p.4500-4506

2010

Volltextzugriff (PDF)

IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria

PloS one, 2014-03, Vol.9 (3), p.e90725-e90725

2014

Volltextzugriff (PDF)

Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

Haematologica (Roma), 2012-04, Vol.97 (4), p.599-607

2012

Volltextzugriff (PDF)

Chronic Lymphocytic Leukemia

The New England journal of medicine, 2005-02, Vol.352 (8), p.804-815

2005

Volltextzugriff (PDF)

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Frontiers in oncology, 2022-07, Vol.12, p.897280-897280

2022

Volltextzugriff (PDF)

Chronic Lymphocytic Leukemia

Cold Spring Harbor perspectives in medicine, 2021-02, Vol.11 (2), p.a035220

2021

Volltextzugriff (PDF)

Binding of CLL subset 4 B-cell receptor immunoglobulins to viable human memory B lymphocytes requires a distinctive IGKV somatic mutation

Molecular medicine (Cambridge, Mass.), 2017-01, Vol.23 (1), p.1-12

2017

Volltextzugriff (PDF)

Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer

Carcinogenesis (New York), 2010-02, Vol.31 (2), p.208-215

2010

Volltextzugriff (PDF)

Activated CLL cells regulate IL-17F–producing Th17 cells in miR155-dependent and outcome-specific manners

JCI insight, 2022-06, Vol.7 (12)

2022

Volltextzugriff (PDF)

1 – 25 von 386

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(369)
Mit Volltextzugriff
(361)

Publikationsform

Sprache

Englisch
(385)
Japanisch
(18)
Russisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options

B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia

Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL)—Then and now

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen

A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia

CLL stereotyped B-cell receptor immunoglobulin sequences are recurrent in the B-cell repertoire of healthy individuals: Apparent lack of central and early peripheral tolerance censoring

Correction to: Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells

Characterization of the Intraclonal Complexity of Chronic Lymphocytic Leukemia B Cells: Potential Influences of B-Cell Receptor Crosstalk with Other Stimuli

Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria

Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

Chronic Lymphocytic Leukemia

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Binding of CLL subset 4 B-cell receptor immunoglobulins to viable human memory B lymphocytes requires a distinctive IGKV somatic mutation

Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer

Activated CLL cells regulate IL-17F–producing Th17 cells in miR155-dependent and outcome-specific manners

Suchergebnisse filtern